Please wait while the formulary information is being retrieved.
Drug overview for HALLS DEFENSE (ascorbic acid):
Generic name: ASCORBIC ACID (as-KORE-bik AS-id)
Drug class: Vitamin C
Therapeutic class: Electrolyte Balance-Nutritional Products
Ascorbic acid is the functional and principal in vivo form of vitamin C, an essential water-soluble vitamin.
No enhanced Uses information available for this drug.
Generic name: ASCORBIC ACID (as-KORE-bik AS-id)
Drug class: Vitamin C
Therapeutic class: Electrolyte Balance-Nutritional Products
Ascorbic acid is the functional and principal in vivo form of vitamin C, an essential water-soluble vitamin.
No enhanced Uses information available for this drug.
DRUG IMAGES
No Image Available
The following indications for HALLS DEFENSE (ascorbic acid) have been approved by the FDA:
Indications:
Vitamin C deficiency
Professional Synonyms:
Ascorbic acid deficiency
Scurvy
Indications:
Vitamin C deficiency
Professional Synonyms:
Ascorbic acid deficiency
Scurvy
The following dosing information is available for HALLS DEFENSE (ascorbic acid):
No enhanced Dosing information available for this drug.
Ascorbic acid is usually administered orally. When oral administration is not feasible or when malabsorption is suspected, the drug may be administered IM, IV, or subcutaneously. When given parenterally, utilization of the vitamin reportedly is best after IM administration and that is the preferred parenteral route.
No dosing information available.
No generic dosing information available.
The following drug interaction information is available for HALLS DEFENSE (ascorbic acid):
There are 0 contraindications.
There are 0 severe interactions.
There are 1 moderate interactions.
The clinician should assess the patient’s characteristics and take action as needed. Actions required for moderate interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration.
| Drug Interaction | Drug Names |
|---|---|
| Deferoxamine/Ascorbic Acid (Vitamin C) SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: It is believed that ascorbic acid increases the iron available for chelation from an labile intracellular iron pool. Ascorbic acid may then facilitate iron-induced oxidative tissue damage.(1) CLINICAL EFFECTS: Dietary ascorbic acid may increase the absorption of dietary iron. Supplemental ascorbic acid therapy given during chelation therapy may improve iron output;(1-9) however, excessive dosages may result in cardiac toxicity from iron-induced oxidative tissue damage.(1,2,11-13) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Ascorbic acid intake is often restricted in patients with iron overload; however, it has been used in conjunction with deferoxamine to increase iron excretion.(2) Supplemental ascorbic acid therapy should only be initiated after one month of deferoxamine therapy. Ascorbic acid therapy should only be given in patients receiving deferoxamine regularly and the dose should be given after the infusion has started. The dosage of ascorbic acid should be limited to 50 mg daily in children under 10 years of age; 100 mg daily in older children; and 200 mg daily, in divided doses, in adults.(2) Cardiac function should be monitored in patients receiving concurrent therapy. Discontinue ascorbic acid therapy in patients who develop cardiac dysfunction.(2) DISCUSSION: Supplemental ascorbic acid therapy given during chelation therapy has been shown to improve iron output,(1-9) possibly by increasing iron available for chelation from an labile intracellular iron pool.(1) However, dosages in excess of 500 mg daily have been associated with cardiac dysfunction.(1,2,11-13) |
DEFEROXAMINE MESYLATE, DESFERAL MESYLATE |
The following contraindication information is available for HALLS DEFENSE (ascorbic acid):
Drug contraindication overview.
No enhanced Contraindications information available for this drug.
No enhanced Contraindications information available for this drug.
There are 1 contraindications.
Absolute contraindication.
| Contraindication List |
|---|
| Hemolytic anemia from pyruvate kinase and g6PD deficiencies |
There are 3 severe contraindications.
Adequate patient monitoring is recommended for safer drug use.
| Severe List |
|---|
| Calcium oxalate renal calculi |
| Glucose-6-phosphate dehydrogenase (g6Pd) deficiency |
| Hyperoxaluria |
There are 3 moderate contraindications.
Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.
| Moderate List |
|---|
| Hemochromatosis |
| Kidney disease with reduction in glomerular filtration rate (GFr) |
| Sickle cell disease |
The following adverse reaction information is available for HALLS DEFENSE (ascorbic acid):
Adverse reaction overview.
No enhanced Common Adverse Effects information available for this drug.
No enhanced Common Adverse Effects information available for this drug.
There are 0 severe adverse reactions.
There are 12 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. | None. |
| Rare/Very Rare |
|---|
|
Abdominal pain with cramps Diarrhea Drowsy Fatigue Flushing Headache disorder Heartburn Hyperoxaluria Increased urinary frequency Insomnia Nausea Vomiting |
The following precautions are available for HALLS DEFENSE (ascorbic acid):
No enhanced Pediatric Use information available for this drug.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
No enhanced Pregnancy information available for this drug.
No enhanced Lactation information available for this drug.
No enhanced Geriatric Use information available for this drug.
The following prioritized warning is available for HALLS DEFENSE (ascorbic acid):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for HALLS DEFENSE (ascorbic acid)'s list of indications:
| Vitamin C deficiency | |
| E54 | Ascorbic acid deficiency |
Formulary Reference Tool